Last reviewed · How we verify
NCT05757856
A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis
Phase 2 trial testing NDX-3315 and NDX-3324 in Eosinophilic Esophagitis in 34 participants. Completed in 22 May 2025.
22 May 2025
Quick facts
| Lead sponsor | NexEos Diagnostics, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 34 |
| Start date | 20 January 2023 |
| Primary completion | 22 May 2025 |
| Estimated completion | 22 May 2025 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- NDX-3315 and NDX-3324 — full drug profile →
Conditions studied
- Eosinophilic Esophagitis — all drugs for Eosinophilic Esophagitis →
Sponsor
NexEos Diagnostics, Inc. — full company profile →
Who can join
Adults 18 to 65, any sex, with Eosinophilic Esophagitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open-label phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases.
Low EE, Dellon ES. · · 2024 · cited 22× · PMID 38135920 · DOI 10.1111/apt.17845
Verify or expand the search:
- PubMed search for NCT05757856
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Eosinophilic Esophagitis
Currently open trials in the same condition.
- NCT07027826 — The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in · NA · recruiting
- NCT07227506 — Utility of Mucosal Impedance Device in Chronic Esophageal Disorders: · recruiting
- NCT06972147 — Prevalence and Description of FIRE (Food Induced Immediate Response of the Esophagus) in the Pediatric Population With E · recruiting
- NCT06695897 — A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patie · recruiting
- NCT06443346 — Prospective Registry of EoSinophilic esOphagitis · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05757856 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NexEos Diagnostics, Inc.
- Last refreshed: 11 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05757856.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing